GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-12 22:10 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 289.0 KB | ||
| 2023-06-30 07:00 |
Ipsen et GENFIT annoncent les résultats positifs de l'essai de Phase III ELATIV…
|
French | 275.1 KB | ||
| 2023-06-30 07:00 |
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of ela…
|
English | 226.5 KB | ||
| 2023-06-07 22:10 |
GENFIT annonce de nouvelles données au congrès 2023 de l’European Association f…
|
French | 212.5 KB | ||
| 2023-06-07 22:10 |
GENFIT Announces New Data at the European Association for the Study of the Live…
|
English | 164.3 KB | ||
| 2023-05-31 22:10 |
GENFIT renforce sa franchise ACLF avec un troisième composé de stade clinique
|
French | 333.6 KB | ||
| 2023-05-31 22:10 |
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
|
English | 757.0 KB | ||
| 2023-05-24 19:00 |
GENFIT: May 24, 2023 Combined Shareholders Meeting results
|
English | 154.3 KB | ||
| 2023-05-24 19:00 |
GENFIT : Résultats de l’Assemblée Générale Mixte du 24 mai 2023
|
French | 155.1 KB | ||
| 2023-05-23 22:10 |
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the…
|
English | 168.7 KB | ||
| 2023-05-23 22:10 |
GENFIT annonce la publication présentant le développement et la validation de N…
|
French | 168.3 KB | ||
| 2023-05-11 22:10 |
GENFIT : Information financière du premier trimestre 2023
|
French | 193.0 KB | ||
| 2023-05-11 22:10 |
GENFIT Reports First Quarter 2023 Financial Information
|
English | 190.9 KB | ||
| 2023-05-09 22:10 |
GENFIT présente des données cliniques de Phase 1 d’évaluation de NTZ dans le ca…
|
French | 173.1 KB | ||
| 2023-05-09 22:10 |
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week®…
|
English | 159.8 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
